Biotechnology News

Browse the latest Biotechnology news. Use the menu or navigation tiles to change industry or topic.

April 09, 2026 16:21 ET | Source: Sobi, Inc.

Sobi reçoit l’autorisation par Santé Canada pour EMPAVELIMD (pegcétacoplan) dans le traitement de la GC3 et de la GNMP-CI primitive.

EMPAVELIMD (pegcétacoplan) est le premier traitement autorisé dans le traitement des patients adultes et pédiatriques de 12 ans et plus atteints de glomérulopathie à dépôts de C3 (GC3) ou de...
April 09, 2026 16:21 ET | Source: Sobi, Inc.

Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced...

Browse the latest Healthcare Providers news. Use the menu or navigation tiles to change industry or topic.

Browse the latest Medical Equipment news. Use the menu or navigation tiles to change industry or topic.

Browse the latest Medical Supplies and Services news. Use the menu or navigation tiles to change industry or topic.

Browse the latest Pharmaceuticals news. Use the menu or navigation tiles to change industry or topic.

Browse the latest Cannabis Producers news. Use the menu or navigation tiles to change industry or topic.

View All